Berkeley Lights is a digital cell biology company working to accelerate the discovery, development, and delivery of cell-based products. Developed platforms automate the manipulation, analysis and selection of individual cells to empower engineering of personalized therapies and antibody discovery.
Berkeley Lights completed its IPO in 2020 and has established market leadership in digital cell biology.
Eric Hobbs, Keith Breinlinger
Why we backed Berkeley Lights?
Macro trends in pharma and biotech innovation suggested the need for platforms that enabled rapid and data-led innovation. There was growing biopharmaceutical industry driving demand for cell line development procedures.
Most biopharma companies use cells as an expression host for recombinant monoclonal antibody production. The increase in demand for monoclonal antibodies, cancer therapeutics, and availability of advanced technologies to produce novel cell lines propelled the growth of Berkeley Lights' platform.